Portland, OR -- (SBWIRE) -- 09/07/2017 -- Biosimilar monoclonal antibodies (mAbs) are complex, large proteins of the biosimilar family used by the immune system to identify and neutralize foreign bodies, such as bacteria, viruses, and others. These antibodies are normally administered in the treatment of diseases such as rheumatoid arthritis, Hodgkins lymphoma, chronic lymphocytic leukemia, and others.
The introduction of advanced mAbs is expected drive the global Biosimilar Monoclonal Antibody Market. Furthermore, growth in geriatric population globally and increase in prevalence of diseases, such as rheumatoid arthritis and cancer, boost the market growth. However, stringent government regulations towards the absence of pre-analytical tests impede this growth.
The global biosimilar monoclonal antibody market is segmented on the basis of type, application, and geography. By type, it is divided into synthetic chemicals, biopharmaceuticals, and others. The application segment includes chronic & autoimmune diseases, oncology, and others. Based on region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Comprehensive competitive analysis and profiles of major players, such as Biocon, Accord Healthcare, AET Biotech, Amgen, Celltrion, Reddy's Laboratories, Hospira, 3SBio, Allergan and Alvartis Pharma, are provided in this report.
Get PDF Brochure of this report: https://www.alliedmarketresearch.com/request-toc-and-sample/3671
-The study provides an in-depth analysis of the market with current trends and future estimations to elucidate the imminent investment pockets.
-It offers a quantitative analysis from 2017 to 2023 to enable the stakeholders to capitalize on the prevailing market opportunities.
-Comprehensive analysis of all geographical regions is provided to determine the prevailing opportunities.
-Key players are profiled and their strategies are analyzed thoroughly to understand the competitive outlook of the global market.
-Extensive analysis by product elucidates the use of biosimilar monoclonal antibodies in the medical settings.
Early buyers will receive 20% customization on this report